Source: International Congress 2014 – Open discussion on long-term therapy to reduce exacerbations and closing remarks
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Open discussion on long-term therapy to reduce exacerbations and closing remarks. International Congress 2014 – Open discussion on long-term therapy to reduce exacerbations and closing remarks

Member's Comments

No comment yet.

Related content which might interest you: Systematic review: Does antibiotic treatment duration affect the outcomes of asthma and COPD exacerbations? Source: International Congress 2017 – COPD: microbiome composition and the role of antibiotics Year: 2017 Early detection of asthma exacerbations and the use of action points for treatment decisions in self-management plans Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Evolving use of long-term NIV in COPD: Are we getting it right Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Filling the gaps: future treatment options for mild asthma Source: International Congress 2018 – The complexities of managing mild asthma Year: 2018 Prevention of COPD exacerbations: medications and other controversies Source: ERJ Open Res 2015; 1: 00011-2015 Year: 2015 What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement Source: Eur Respir J, 52 (5) 1801261; 10.1183/13993003.01261-2018 Year: 2018 It is time to further expand research in tailoring self-management of COPD exacerbations! Source: Eur Respir J, 55 (1) 1902225; 10.1183/13993003.02225-2019 Year: 2020 Recommendations on long-term antibiotics and mucolytics for prevention of exacerbations of COPD Source: International Congress 2017 – Treatment and prevention of COPD exacerbation Year: 2017 Hospital treatment costs of exacerbations in COPD patients with indications for LTOT Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Therapeutic options for COPD exacerbations Source: International Congress 2014 – PG04 Update on COPD exacerbations Year: 2014 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature Source: Eur Respir J, 52 (4) 1800703; 10.1183/13993003.00703-2018 Year: 2018 Pharmacological treatment optimisation for stable COPD: an endless story? Source: Eur Respir J, 50 (4) 1701250; 10.1183/13993003.01250-2017 Year: 2017